Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Adult patients, ≥18 years of age~* Rheumatoid arthritis for ≥ 3 months~* Inadequate clinical response to methotrexate at a dose of 7.5-25mg/week for ≥ 12 weeks~Exclusion criteria:~* Rheumatic autoimmune disease or inflammatory joint disease, other than RA~* Prior receipt of any biologic therapy for RA~* Concurrent treatment with any DMARD (other than methotrexate)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo × 2 IV + MTX (Type: PLACEBO_COMPARATOR): Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.
- Ocrelizumab 200 mg × 2 IV + MTX (Type: EXPERIMENTAL): Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
- Ocrelizumab 500 mg × 2 IV + MTX (Type: PLACEBO_COMPARATOR): Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).